COLUMBUS, Ohio – Dr. Carlo M. Croce
, chair of the department of molecular virology, immunology, and medical genetics; and director of Human Cancer Genetics at Ohio State, received the Association for Molecular Pathology
(AMP) Award for Excellence in Molecular Diagnostics. This award, the highest AMP recognition, identifies lifetime innovative and extraordinary achievements by professionals in the fields of molecular biology, molecular pathology, pathology, genetics, microbiology and basic medical sciences.
Croce received the award, sponsored by Roche Molecular Diagnostics, for his achievements in the field of molecular pathology. Croce’s renowned career in research has uncovered early events involved in the pathogenesis of leukemia, lymphoma, lung, nasopharyngeal, head and neck, esophageal, gastrointestinal and breast cancers. More recently, he discovered the novel role of microRNAs in the genesis of various cancers.
AMP is a nonprofit scientific organization made up of approximately 1,700 molecular laboratory scientists performing research, education, and testing for molecular diagnosis of solid tumors, disorders and diseases.
Croce, also the John W. Wolfe Chair in Human Cancer Genetics and director of the human cancer genetics program in The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, recently received one of the nation’s highest honors with his induction as a member of the Institute of Medicine of the National Academies.
Croce, a member of the National Academy of Sciences in the United States and the Accademia Nazionale delle Scienze detta dei XL in Italy, has received numerous awards for cancer research. He is principal investigator on 11 federal research grants and has more than 900 peer-reviewed, published research papers.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute
(NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 210-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S. News and World Report.